Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips Sells 25,343 Shares

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 25,343 shares of the business’s stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $0.65, for a total value of $16,472.95. Following the completion of the sale, the chief executive officer now directly owns 191,374 shares of the company’s stock, valued at approximately $124,393.10. The trade was a 11.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Accelerate Diagnostics Stock Performance

Shares of NASDAQ AXDX opened at $0.62 on Tuesday. The business’s 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.39. Accelerate Diagnostics, Inc. has a 52 week low of $0.62 and a 52 week high of $2.09. The firm has a market cap of $15.68 million, a price-to-earnings ratio of -0.22 and a beta of 0.46.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings results on Thursday, March 20th. The medical research company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.13. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $3.00 million. As a group, equities research analysts forecast that Accelerate Diagnostics, Inc. will post -2.3 earnings per share for the current year.

Analyst Ratings Changes

AXDX has been the subject of a number of analyst reports. StockNews.com initiated coverage on shares of Accelerate Diagnostics in a research note on Wednesday, April 2nd. They issued a “hold” rating for the company. BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AXDX. Jane Street Group LLC bought a new stake in Accelerate Diagnostics during the fourth quarter valued at about $27,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter worth about $34,000. Renaissance Technologies LLC boosted its stake in Accelerate Diagnostics by 160.6% during the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 65,984 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Accelerate Diagnostics by 6.9% in the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after buying an additional 8,777 shares during the last quarter. Institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.